The aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3653-3657

  Heideman, D A M ^a   Hesselink, A T ^a   Van Kemenade, F J ^a   Iftner, T ^b   Berkhof, J ^a   Topal, F ^a   Agard, D ^a   Meijer, C J L M ^a   Snijders, P J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN E6; PROTEIN E7; VIRUS DNA;

ADULT; ARTICLE; CANCER GRADING; CANCER SCREENING; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84886563011     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01517-13     Document Type: Article

References (25)

1. Dockter J, Schroder A, Eaton B, Wang A, Sikhamsay N, Morales L, Giachetti C.2009.Analytical characterization of the APTIMA HPV assay.J. Clin. Virol.45(Suppl 1):S39-S47.
2. Getman D, Aiyer A, Dockter J, Giachetti C, Zhang F, Ginocchio CC.2009.Efficiency of the APTIMAHPVassay for detection ofHPVRNAand DNA targets.J. Clin. Virol.45(Suppl 1):S49-S54.
3. Hologic Gen-Probe.2011.APTIMA HPV assay package insert.Hologic Gen-Probe Inc., San Diego, CA.
4. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.2012.Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Vaccine 30(Suppl 5):F88-F99.
5. Murphy J, Kennedy EB, Dunn S, McLachlin CM, Fung Kee Fung M, Gzik D, Shier M, Paszat L.2012.HPV testing in primary cervical screening: a systematic review and meta-analysis.J.Obstet.Gynaecol.Can.34: 443-452.
6. Meijer CJ, Berkhof J, Heideman DA, Hesselink AT, Snijders PJ.2009.Validation of high-risk HPV tests for primary cervical screening.J. Clin. Virol.46(Suppl 3):S1-S4.
7. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ.2009.Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.Int.J.Cancer 124:516-520.
8. Snijders PJF, Van den Brule AJC, Jacobs MV, Pol RP, Meijer CJLM.2005.HPV DNA detection and typing in cervical scrapes.Methods Mol.Med.119:101-114.
9. van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ.2002.GP5-/6-PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes.J. Clin. Microbiol.40:779-787.
10. Hesselink AT, Meijer CJLM, Poljak M, Berkhof J, van Kemenade FJ, van der Salm ML, Bogaarts M, Snijders PJF, Heideman DAM.2013.Clinical validation of the Abbott RealTime High Risk HPV assay according to the guidelines for human papillomavirusDNAtest requirements for cervical screening.J. Clin. Microbiol.51:2409-2410.
11. Hesselink AT, Heideman DA, Berkhof J, Topal F, Pol RP, Meijer CJ, Snijders PJ.2010.Comparison of the clinical performance of Papillo-Check human papillomavirus detection with that of the GP5-/6-PCRenzyme immunoassay in population-based cervical screening.J. Clin. Microbiol.48:797-801.
12. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Young M, Stoler M, McCarthy J, Wright C, Bergeron C, Soutter WP, Lyons D, Cuzick J.2012.Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study.J. Clin. Microbiol.50:1867-1873.
13. Clad A, Reuschenbach M, Weinschenk J, Grote R, Rahmsdorf J, Freudenberg N.2011.Performance of the Aptima high-risk human papillomavirus mRNA assay in a referral population in comparison with Hybrid Capture 2 and cytology.J. Clin. Microbiol.49:1071-1076.
14. Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, Booth C, Pérez AG, Chávez-Avilés MN, Belinson J.2013.Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.Int.J.Gynecol.Cancer 23:513-518.
15. Stoler MH, Wright TC, Jr, Cuzick J, Dockter J, Reid JL, Getman D, Giachetti C.2013.APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results.Am.J.Obstet.Gynecol.208:144. e1-144.e8.
16. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, Reuschenbach M, Belinson S, Belinson JL, Monsonego J.2013.The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.Int.J.Cancer 132:101-108.
17. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter P, Lyons D, Cuzick J.2008.Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears.Cancer Epidemiol.Biomarkers Prev.17:3033-3042.
18. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Halfon P, Ruiz F, Smith JS.2011.Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.Int.J.Cancer 129:691-701.
19. Wu R, Belinson SE, Du H, Na W, Qu X, Wu R, Liu Y, Wang C, Zhou Y, Zhang L, Belinson JL.2010.Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.Int.J.Gynecol.Cancer 20:1411-1414.
20. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Smith JS.2012.Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).Gynecol.Oncol.125:175-180.
21. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, Ghatage P, Gadag V, Holloway G, Bartellas E, Kum N, Giede C, Lear A.2011.Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.J. Clin. Microbiol.49: 557-564.
22. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C.2009.Clinical performance of the APTIMAHPVAssay for the detection of high-risk HPV and high-grade cervical lesions.J. Clin. Virol.45(Suppl 1):S55-S61.
23. Mesher D, Szarewski A, Cadman L, Austin J, Ashdown-Barr L, Ho L, Terry G, Young M, Stoler M, Bergeron C, McCarthy J, Wright C, Liddle S, Soutter WP, Lyons D, Cuzick J.2013.Comparison of human papillomavirus testing strategies for triage of women referred with low-grade cytological abnormalities.Eur.J.Cancer 49:2179-2186.
24. Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Wright C, Lyons D, Szarewski A.2013.Comparing the performance of six human papillomavirus tests in a screening population.Br.J.Cancer 108:908-913.
25. Broccolo F, Fusetti L, Rosini S, Caraceni D, Zappacosta R, Ciccocioppo L, Matteoli B, Halfon P, Malnati MS, Ceccherini-Nelli L.2013.Comparison of oncogenic HPV type-specific viralDNAload and E6/E7mRNA detection in cervical samples: results from a multicenter study.J.Med.Virol.85:472-482.